Nebivolol PCD Pharma Franchise Company
Cafoli Lifecare offers 10 Nebivolol formulations in tablet form, including antihypertensive combinations, for its cardiac franchise partners. All products are manufactured at WHO-GMP certified facilities and offered on a monopoly basis.
What is Nebivolol?
Nebivolol is a third-generation, highly beta-1 selective adrenergic blocker. In addition to reducing heart rate and cardiac workload, it stimulates endothelial nitric oxide release, producing vasodilation and lowering peripheral vascular resistance. More detail is available on MedlinePlus.
Therapeutic Applications
Nebivolol is used in essential hypertension, as an adjunct in chronic heart failure, and in patients requiring a beta-blocker with a favourable metabolic and tolerability profile. It is prescribed by cardiologists and consultant physicians.
Why Nebivolol is a High-Potential Molecule for Distributors
Nebivolol's nitric-oxide-mediated vasodilation and high beta-1 selectivity mean fewer complaints of fatigue, sexual dysfunction and blood-sugar disturbance than with older beta-blockers — the reasons patients abandon therapy. Cardiologists are therefore switching hypertensive and diabetic patients onto it, giving the molecule a growing share of a lifelong-therapy market.
Why Choose Cafoli Lifecare
Cafoli provides district-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, competitive net rates and complete promotional inputs, with 1000+ franchise partners across India.
References
- MedlinePlus: Nebivolol
- PubChem: Nebivolol
Our formulations of Nebivolol find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: